These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

967 related articles for article (PubMed ID: 32179179)

  • 1. Immune Checkpoint Inhibitors in Thoracic Malignancies: Review of the Existing Evidence by an IASLC Expert Panel and Recommendations.
    Remon J; Passiglia F; Ahn MJ; Barlesi F; Forde PM; Garon EB; Gettinger S; Goldberg SB; Herbst RS; Horn L; Kubota K; Lu S; Mezquita L; Paz-Ares L; Popat S; Schalper KA; Skoulidis F; Reck M; Adjei AA; Scagliotti GV
    J Thorac Oncol; 2020 Jun; 15(6):914-947. PubMed ID: 32179179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy of immune checkpoint inhibitors in thoracic malignancies.
    Remon J; Facchinetti F; Besse B
    Eur Respir Rev; 2021 Dec; 30(162):. PubMed ID: 34615702
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Not Available].
    Mignard X; Chaabane N; Fallet V; Wislez M
    Bull Cancer; 2018 Dec; 105 Suppl 1():S16-S23. PubMed ID: 30595194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-line immunotherapy in advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an International Expert Panel Meeting by the Italian Association of Thoracic Oncology.
    Gridelli C; Peters S; Mok T; Forde PM; Reck M; Attili I; de Marinis F
    ESMO Open; 2022 Feb; 7(1):100355. PubMed ID: 34922299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Moving Immune Checkpoint Blockade in Thoracic Tumors beyond NSCLC.
    Facchinetti F; Marabelle A; Rossi G; Soria JC; Besse B; Tiseo M
    J Thorac Oncol; 2016 Nov; 11(11):1819-1836. PubMed ID: 27288978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced-Stage Non-Small Cell Lung Cancer: Advances in Thoracic Oncology 2018.
    Remon J; Ahn MJ; Girard N; Johnson M; Kim DW; Lopes G; Pillai RN; Solomon B; Villacampa G; Zhou Q
    J Thorac Oncol; 2019 Jul; 14(7):1134-1155. PubMed ID: 31002952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies.
    Andrini E; Federico AD; Sisi M; Rosellini M; Palladini A; Lamberti G; Giglio A; Gelsomino F
    Immunotherapy; 2022 Nov; 14(16):1329-1340. PubMed ID: 36382476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of Immunotherapy in Small Cell Lung Cancer, Thymic Epithelial Tumors, and Mesothelioma.
    Hann CL; Scherpereel A; Hellyer JA; Wakelee HA
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():543-552. PubMed ID: 31099677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.
    Govindan R; Aggarwal C; Antonia SJ; Davies M; Dubinett SM; Ferris A; Forde PM; Garon EB; Goldberg SB; Hassan R; Hellmann MD; Hirsch FR; Johnson ML; Malik S; Morgensztern D; Neal JW; Patel JD; Rimm DL; Sagorsky S; Schwartz LH; Sepesi B; Herbst RS
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35640927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Assi HI; Kamphorst AO; Moukalled NM; Ramalingam SS
    Cancer; 2018 Jan; 124(2):248-261. PubMed ID: 29211297
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT).
    Gridelli C; Peters S; Velcheti V; Attili I; de Marinis F
    ESMO Open; 2023 Apr; 8(2):101192. PubMed ID: 36965261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Face to face among different chemo-immunotherapy combinations in the first line treatment of patients with advanced non-small cell lung cancer: Results of an international expert panel meeting by the italian association of thoracic oncology (AIOT).
    Gridelli C; Peters S; Mok T; Garassino M; Paz-Ares L; Attili I; de Marinis F
    Lung Cancer; 2024 Jan; 187():107441. PubMed ID: 38141488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current evidence and future perspectives of immune-checkpoint inhibitors in unresectable malignant pleural mesothelioma.
    Hotta K; Fujimoto N
    J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32098830
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive Biomarkers for Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: Current Status and Future Directions.
    Bhalla S; Doroshow DB; Hirsch FR
    Cancer J; 2020; 26(6):507-516. PubMed ID: 33298722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
    Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
    Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progress in the Management of Advanced Thoracic Malignancies in 2017.
    Ferrara R; Mezquita L; Besse B
    J Thorac Oncol; 2018 Mar; 13(3):301-322. PubMed ID: 29331646
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions.
    Remon J; Vilariño N; Reguart N
    Cancer Treat Rev; 2018 Mar; 64():21-29. PubMed ID: 29454155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant immune checkpoint inhibitors in resectable non-small-cell lung cancer: a systematic review.
    Ulas EB; Dickhoff C; Schneiders FL; Senan S; Bahce I
    ESMO Open; 2021 Oct; 6(5):100244. PubMed ID: 34479033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cutting-edge progress of immune-checkpoint blockade in lung cancer.
    Zhou F; Qiao M; Zhou C
    Cell Mol Immunol; 2021 Feb; 18(2):279-293. PubMed ID: 33177696
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.